

1 ADIPOSE-DERIVED STROMAL VASCULAR FRACTION AND FAT GRAFTS VERSUS MEDICAL
2 TREATMENT FOR TREATING THE HANDS OF PATIENTS WITH SYSTEMIC SCLEROSIS. A
3 RANDOMIZED CRONTOLLED TRIAL

4
5 **Authors**

6
7 Martin Iglesias¹, Iván Torre-Villalvazo², Patricia Butrón-Gandarillas³, Tatiana S.

8 Rodríguez-Reyna⁴, Erik A. Torre-Anaya², Armando R. Tovar-Palacio², Alejandro Zentella-Dehesa⁵,

9 Martha Guevara-Cruz², Alan M Hernández-Campos³.

10

11 **Affiliation:**

12 1. Plastic and Reconstructive Surgery Service at Instituto Nacional de Ciencias Médicas y
13 Nutrición, Salvador Zubirán; and Tecnológico de Monterrey, Escuela de Medicina y Ciencias de
14 la Salud, Mexico City, Mexico.

15 2. Nutrition Physiology Department at Instituto Nacional de Ciencias Médicas y Nutrición
16 Salvador Zubirán, Mexico City, Mexico.

17 3. Plastic and Reconstructive Surgery Service at Instituto Nacional de Ciencias Médicas y
18 Nutrición Salvador Zubirán, Mexico City, Mexico.

19 4. Rheumatology Department at Instituto Nacional de Ciencias Médicas y Nutrición Salvador
20 Zubirán, Mexico City, Mexico.

21 5. Biochemistry Laboratory at Instituto Nacional de Ciencias Médicas y Nutrición Salvador
22 Zubirán, Mexico City, Mexico.

23 **Corresponding author**

24 Martin Iglesias.

25 Monte de Antisana 47, Jardines en la Montaña, Tlalpan, CP 14210, Mexico City, Mexico

26 iglesias@drmartiniglesias.com

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57 **ABSTRACT**

58

59 **Background.** In the hand, the Systemic Sclerosis (SS) is characteristically evidenced by Raynaud's
60 phenomenon (RP) and fibrosis of the skin, tendons, ligaments, and joints as well as digital ulcers
61 with prolonged healing. Current medical treatment not always cure these complications. Local
62 adipose-derived stromal vascular fraction (ADSVF) administration into the hands has been
63 proposed as an emerging treatment for these complications, due to its proangiogenic,
64 antifibrotic, and immunoregulatory activities. The objective of this controlled trial was to
65 evaluate the safety and clinical effects of fat micrografts plus ADSVF administration into the
66 hands of patients with SS.

67 **Methods.** This was an open-label, monocentric, randomized controlled study. Twenty patients
68 diagnosed with SS were enrolled and assigned to the experimental or control group. Fat
69 micrografts plus the ADSVF were injected into the right hand of experimental group patients.
70 The control group continued to receive only medical treatment. Demographic, serologic data
71 and disease severity were recorded. Digital oximetry, pain, Raynaud phenomenon (RP), digital
72 ulcer healing (DUH), mobility, thumb opposition, vascular density of the nail bed, skin affection
73 of the hand, Serologic antibodies, hand function, and quality of life scores were evaluated in
74 both groups. The mean follow-up period was 168 days.

75 The differences between before and after the intervention were analyzed with the Wilcoxon
76 range test, and the differences between the control and experimental groups at 0 days and 168
77 days were analyzed with the Mann–Whitney U test.

78 **Results.** Adverse events were not observed in both groups. There were no changes in disease
79 severity, serologic antibodies, nailfold capillaroscopy patterns, mobility, and hand function in
80 both groups. There were significant improvements in pain, DUH and quality of life scores in the
81 experimental group. RP improved significantly in both groups. However, on statistically
82 comparing the results at 168 days between the groups, significant improvements were only
83 observed in pain levels ($p = 0.02$) and DUH ($p=0.003$).

84 **Conclusions.** The injection of ADSVF plus fat micrografts is a reproducible, and safe technique.
85 Pain and digital ulcers in the hands of patients with SS can be treated with this treatment.

86 **Trial Registration:** Retrospectively registered in ClinicalTrials.gov with identifier NCT04387825

87 **Keywords:** hand therapy; adipose derived vascular stromal fraction; systemic sclerosis; adipose
88 mesenchymal stem cells; regenerative medicine.

89

90

91

92 INTRODUCTION

93 Systemic sclerosis (SS) is characterized by the presence of functional and structural
94 microvasculopathy resulting in ischemia that leads to cutaneous and visceral fibrosis. In the
95 hand, this disease is characteristically evidenced by Raynaud's phenomenon (RP) and fibrosis of
96 the skin, tendons, ligaments, and joints.[[1,2,3,4](#)] Further, the hand is affected in 47 to 97% of
97 the SS cases.[[5, 6](#)] Permanent ischemia and skin fibrosis can lead to the appearance of digital
98 ulcers that result in prolonged healing durations, recurrences, and infections and may culminate
99 in digital amputation. This musculoskeletal involvement is one of the main etiologies of pain,
100 devastating disability, and a dramatic decrease in the quality of life of patients with SS.[[6, 7](#)]-The
101 current treatment is the control of the disease with medications and rehabilitation.[[8](#)] However,
102 these options only temporarily control the symptoms but do not decrease the time period
103 required for ulcer healing or improve hand function.

104 The presence of adipose stem cells (ASCs) in the adipose-derived stromal vascular fraction
105 (ADSVF) was described by Zuk et al. in 2002.[[9](#)] Because these cells are multipotent with local
106 angiogenic, anti-inflammatory, antifibrotic, immunomodulatory, and regenerative properties
107 and because of their abundance in fat, easy acquisition, and almost immediate availability for
108 use, ADSVF administration has positioned itself as an alternative treatment for immunological
109 diseases that cause ischemia and cutaneous fibrosis, which are also the main manifestations of
110 SS.[[9-21](#)]

111

112 Bank et al. infiltrated decanted fat only in order to treat RP and obtained extraordinary results
113 in terms of improving pain and RP.[22] Del Papa et al. centrifuged fat and injected the
114 intermediate layer into patients with SS and active digital ulcers that were resistant to
115 conventional treatment.[14, 15] Subsequently, Del Papa et al. reported on the same technique
116 in a controlled study in 2019. The digital ulcers healed after a mean period of 8 weeks with the
117 reduction of pain and formation of new capillaries.[23]

118 Granel et al. administered the ADSVF to 12 patients who predominantly had limited cutaneous
119 SS with no severe involvement of the internal organs. Subsequently, they reported
120 improvements in pain and the frequency and intensity of RP; the healing of digital ulcers that
121 were resistant to conventional treatments; improved strength, movement, and Cochin
122 functional scale scores; and a decrease in the digital circumference.[24] Further, these results
123 were reported to persist for 12, 22, and 30 months postoperatively with additional
124 improvements in nail appearance and health based on improved Scleroderma Health
125 Assessment Questionnaire scores, the ability to participate in household activities, and the
126 approval of the procedure by the patients themselves.[21, 25, 26] Del Papa et al. and Granel et
127 al. reported that the treatment was safe and well tolerated.[14, 24]

128 Lipoatrophy may develop in patients with SS due to the loss of adipocytes and defective stem
129 cell function.[13, 27] Thus, there is a good possibility that the hands of patients with SS could be
130 treated with ADSVF plus fat grafts with the from proximal sites, such as the abdominal wall. For
131 these reasons and because there has been only one controlled trial, we designed this controlled

132 clinical trial with the aim of evaluating the safety, reproducibility, and clinical effects of treating
133 the hands of patients affected with SS with the administration ADSVF plus fat micrografts.

134

135 **METHODS**

136 This open-label, monocentric, randomized controlled pilot study was approved by the
137 Institutional Review Committee with the reference, SCI-1505-15/15-1, and was registered with
138 ClinicalTrials.gov under the identifier, NCT04387825. We used a random number table to assign
139 patients into different groups. Informed consent to participate in this study was obtained from
140 all the participants. Both the experimental and control groups contained 10 patients each who
141 were diagnosed with SS according to the criteria of the American College of Rheumatology and
142 LeRoy-Medsger criteria. All the patients were aged > 18 years and had BMIs > 18 kg/m². All the
143 patients had undergone stable vasoactive and immunosuppressive therapies for at least 1
144 month before enrollment in the study, and these treatments were continued unchanged
145 throughout the study period. The exclusion criteria were infected digital ulcers, comorbidities
146 that could affect hand function, alcoholism, and/or drug abuse. It was decided that the
147 treatment would be administered to the most affected hand of the patients, which was the
148 right hand in the entire experimental group. ADSVF and fat micrografts were administered in
149 the experimental group. The evolution of the disease and the medical therapy effects were
150 observed in the control group. Demographic and serologic data were recorded as well as

151 disease severity according to the Medsger severity scale. The evaluated variables and follow-up
 152 times are presented in Table 1.

Table 1. Data Evaluation

Variable	Evaluation method	Follow up in days						
		Preop	28	56	84	112	140	168
Digital Oximetry	Transcutaneous Oximetry	✓	✓	✓	✓	✓	✓	✓
Pain	Numeric scale from 1 to 10	✓	✓	✓	✓	✓	✓	✓
Raynaud Phenomenon	Frequency number of events per day/week; Duration of minutes in every event.	✓	✓	✓	✓	✓	✓	✓
Digital Ulcers	Number of ulcers	✓	✓	✓	✓	✓	✓	✓
Digital TAM*	Digital Manual Goniometry	✓						✓
Thumb opposition	Kapandji Test	✓						✓
Health status and disability index	SHAQ scale	✓						✓
Hand Function	COCHIN scale	✓						✓
Quality of Life	SF-36 scale	✓						✓
Vascular density of the nail bed	Nailfold Videocapillaroscopy	✓						✓
Skin affection of the hand	Modified Rodnan skin score	✓						✓
Antibodies	ANA**, Anti-Topoisomerase I, Anti-centromere, Anti-U1-RNP	✓						✓

*TAM=Total Active Motion

**ANA=Anti-nuclear antibodies

153
 154

155

156 Data regarding the presence of complications, such as compartment syndrome and/or infection,
 157 in both the donor site and treated hand were recorded daily for 1 week.

158 Rheumatological data were retrieved by the rheumatologist group, and medical interns were
159 trained to allocated patients and collect the other data.

160 **Tissue collection and ADSVF preparation**

161
162 Fat grafts were obtained by liposuction under local anesthesia. Briefly, the periumbilical region
163 (9 patients) or posterior thigh (1 patient) was infiltrated with 500 ml of Klein's formula.
164 Liposuction was performed with a 20-ml syringe and 3-mm diameter blunt cannula with 2-mm
165 openings. A total of 100 ml of fat was harvested, from which 60 ml was transferred to sterile
166 flask containing Hank's balanced saline solution with 5% albumin and was immediately
167 transported to the laboratory. The adipose tissue was decanted for 10 minutes in a laminar flow
168 cabinet for fraction separation. The upper fraction comprised disrupted adipocytes (oil), and the
169 lower fraction was a fluid portion containing the anesthetic solution, erythrocytes, and dead
170 cells. These both fractions were removed. The middle fraction was washed twice in phosphate-
171 buffered saline (PBS) (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and subsequently
172 incubated for 20 minutes in a type II collagenase solution (Sigma, St. Louis, MO, USA) in PBS at a
173 concentration of 2 mg/ml of lipoaspirate. This was followed by addition of
174 ethylenediaminetetraacetic acid (Sigma) in PBS. To separate the ADSVF from the floating
175 adipocytes, this digested tissue was centrifuged at $800 \times g$ for 10 minutes. The compacted cells
176 were resuspended in 3 ml of PBS and filtered through a 100- μm mesh cell strainer (Corning Inc.,
177 Corning, NY, USA). A 10 μl aliquot was obtained from each patient to characterize the ADSVF
178 cellular identity by flow cytometric assays. After the fat was processed, 2 ml of the ADSVF was

179 transferred back to the operating room for the autologous transplantation procedure. Another
180 1 ml sample was used for cell quantification, viability determination, and cell culturing to
181 determine the adipocyte differentiation capacity (Figure 1).

182
183 The cells were seeded in 6-well culture plates in Dulbecco's modified Eagle's medium and were
184 supplemented with fetal bovine serum and antibiotic/antifungal agents. Upon reaching 90%
185 confluence, the cells were differentiated into mature adipocytes using a differentiation cocktail
186 (2.5 μ M dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine, 10 μ g/ml insulin). As a control, a
187 plate containing cells in the culture medium was left without adipogenic stimulation. After 20
188 days of differentiation, the cells were stained with oil red to assess fat accumulation (mature
189 adipocyte phenotype), and the fat content in each culture was quantified by spectrophotometry
190 (Figure 1 A-F).

191
192 **ADSVF administration into the hand**
193 A nerve blockade was induced in the median, ulnar, and radial nerves at the wrist level using 2%
194 lidocaine without epinephrine. Subsequently, 40 ml of fat was mixed with 2 ml of the ADSVF
195 and was transferred to 1-ml and 3-ml syringes. Using a 19-gauge blunt cannula (0.8 mm), 1.5 ml
196 was administered along each radial and ulnar neurovascular digital pedicle through small radial
197 and ulnar skin incisions at the level of the interphalangeal and metacarpophalangeal joints.
198 Additionally, 3 ml was administered to each side of the metacarpal trapezius joint, together with

199 the subcutaneous distribution of 10 ml throughout the palm of the hand and even distribution
200 of 10 ml in the back of the hand. The study was carried out from October 2018 to May 2019.

201

202 **Statistical analysis**

203 Continuous variables are expressed as median with 95% confidence interval. Dichotomous
204 variables are expressed as frequency and percentage. Categorical or dichotomous variables
205 were analyzed with Fisher's exact test. The differences between before and after the
206 intervention were analyzed with the Wilcoxon range test, and the differences between the
207 control and experimental groups at 0 days and 168 days were analyzed with the Mann–
208 Whitney U test. The analysis was enhanced to determine the interaction between time (0/168
209 days) and treatment (control/experimental) with analysis of variance for repeated measures,
210 and logarithmic transformation was performed before such analysis. A P value of <0.05 was
211 considered statistically significant of a tail. The data were analyzed using SPSS for Windows,
212 version 24.00 (IBM Corp., Armonk, NY, USA) and GraphPad Prism software version 7 (GraphPad
213 Software, San Diego, CA, USA).

214 **RESULTS**

215 Demographic, serological (antibodies), and disease severity-related data are presented in Table
216 2.

217

218

219

Table 2. Demographic, serological and severity data. Control and experimental groups.

General Data	0 days			168 days		
	Experimental 10	Control 10	P ¹	Experimental 10	Control 9	P
Patient (n)						
Female n (%)	10 (100 %)	9 (95 %)	0.99	10 (100%)	8 (89%)	0.47
Age, mean (95%IC)*	55.0(43.4,58.7)	57.0(45.6,62.5)	0.48	55.1(46.0,62.7)	55.0(43.5,59.0)	0.48
Diffuse Sclerosis, n (%)	8 (80 %)	6 (60 %)	0.62	8 (80 %)	6 (66.66%)	0.62
Antibodies						
ANA positives, n (%)	8 (80 %)	10 (100%)	0.47	8 (80 %)	9 (100%)	0.47
Anti-Topoisomerase I, n (%)	3 (30 %)	2 (20%)	0.99	3 (30 %)	2 (22.2%)	0.99
Anti-centromere, n (%)	3 (30 %)	3 (30%)	0.99	3 (30 %)	3 (33.3%)	0.99
Anti-U1-RNP, n (%)	2 (20 %)	3 (30%)	0.99	2 (20 %)	3 (33.3%)	0.62
Organ Involvement						
Vascular, n (%)	10 (100 %)	10 (100 %)	0.99	8 (80 %)	9 (100%)	0.47
Severe vascular, n (%)	6 (60 %)	7 (70 %)	0.99	2 (20 %)	4 (44.4%)	0.35
Articular, n (%)	10 (100 %)	10 (100 %)	0.99	10 (100 %)	9 (100%)	0.99
Severe articular, n (%)	6 (60 %)	2 (20 %)	0.17	3 (30 %)	3 (33.3%)	0.99
FTP, mean (95%IC)*	3.15(2.30,3.71)	4.00 (2.72,4.39)	0.21	3.50(2.25,4.32)	3.15(2.81,4.00)	0.91
Muscular, n (%)	1 (10 %)	1 (10%)	0.99	3 (30 %)	1 (11.1%)	0.58
Severe muscular, n (%)	0 (-)	0 (-)	0.99	0 (-)	0 (-)	0.99
Gastrointestinal, n (%)	4 (40 %)	5 (50 %)	0.99	5 (50 %)	7 (77.7%)	0.35
Severe gastrointestinal, n (%)	1 (10 %)	1 (10 %)	0.99	1 (10 %)	1 (11.1%)	0.99
Pulmonary, n (%)	6 (60 %)	9 (90%)	0.30	6 (60 %)	9 (100%)	0.08
Severe pulmonary, n (%)	1 (10 %)	1 (10 %)	0.99	1 (10 %)	1 (11.1%)	0.99
HAP, n (%)	2 (20 %)	3 (30 %)	0.99	2 (20 %)	3 (33.3%)	0.62
Severe HAP, n (%)	0 (-)	0 (-)	0.99	0 (-)	0 (-)	0.99
Cardiac, n (%)	1 (10 %)	1 (10 %)	0.99	1 (10 %)	1 (11.1%)	0.99
Severe cardiac, n (%)	0 (-)	0 (-)	0.99	0 (-)	0 (-)	0.99
Renal, n (%)	0 (-)	1 (10%)	0.99	0 (-)	1 (11.1%)	0.47
Severe renal n (%)	0 (-)	0 (-)	0.99	0 (-)	0 (-)	0.99
Capillaroscopic Pattern						
Early phase n(%)	2 (20 %)	1 (10 %)	0.99	3 (30 %)	0 (-)	0.21
Active phase n(%)	0 (-)	1 (10%)	0.99	0 (-)	1 (11.1%)	0.47
Late phase n(%)	8 (80%)	8 (80 %)	0.99	7 (70 %)	9 (100%)	0.21

P¹ Statistical significance analyzed Fisher's exact test.

*Statistical significance analyzed with Mann-Whitney U test

220
221 The baseline characteristics were similar between the two patient groups. All the patients

222 presented with moderately intense vascular and joint conditions. Some patients exhibited
223 severe internal organ involvement. One control group patient withdrew from the study due to
224 personal problems.

225 The total viable nucleated cell numbers and cellular characteristics of the ADSVF are outlined in
226 [Additional file 1 Table A.](#)

227 The abilities to adhere to plastic and differentiate to adipocytes are presented in Figure 1. G-I
228 greater amount of fat content was found in cell cultures induced toward adipocyte
229 differentiation than in control cultures ($p = 0.0001$).

230 At the completion of ADSVF administration, the digits did not exhibit capillary filling, but
231 circulation was reestablished after 2 h. There were no adverse effects. Digital oximetry (SpO₂),
232 digital total active motion, thumb opposition, hand function, health status and disability index,
233 and vascular density of the nail bed, were similar in the two groups at the study's end.

234 The pain score increased from 4.6 to 7.5 in the first week, gradually decreased to reach the
235 basal value at day 7, and subsequently began to decrease further. Significant improvements
236 were observed in pain and quality of life score (Short Form 36) in the experimental group at the
237 study's end. The frequency, intensity and duration of RP have significant improvement in both
238 groups at 168 days, but were more important in the experimental group. The skin affection of
239 the hand improved significantly in the control group. However, when the results at 168 days

240 were statistically compared between the groups, only pain exhibited a significant improvement
 241 ($p = 0.02$) (Table 3 and [Additional file 2 Table B](#)).

Table 3. Results in control and experimental groups

Concept	Group	Day 0	Day 168	P ¹	P ²
Pain	Control	4.00(2.64,6.16)	2.00(1.51,6.04)	0.91	
	Experimental	5.00(3.08,6.12)	0.00(0.00,2.95)*	0.006*	0.02*
Quality of Life (SF-36)	Control	40.0(28.5,46.4)	35.0(17.5-51.3)	0.55	
	Experimental	37.5(32.1-57.8)	45.0(38.7-62.2)	0.04*	0.15
Raynaud Phenomenon <i>Frequency n/week</i>	Control	5.50(2.68,13.1)	00(0.00,03.18)	0.010*	
	Experimental	4.50(2.87,6.33)	0.50(0.10,1.10)	0.005*	0.418
Raynaud Phenomenon <i>Intensity</i>	Control	2.00(1.22,2.18)	0.00(0.00,1.44)	0.03*	
	Experimental	2.00(1.50,2.10)	0.50(0.10,1.10)	0.006*	0.60
Raynaud Phenomenon <i>duration in minutes</i>	Control	17.5(2.12,54.4)	0.00(0.00,10.3)	0.02*	
	Experimental	12.5(6.55,35.6)	0.00(0.00,6.82)	0.005*	0.14
Skin affection of the hand	Control	6.50(2.32,15.8))	5.50(1.42,12.9)	0.05*	
	Experimental	15.0(6.84,17.7)	15.5(6.36,16.6)	0.07	0.19

The sample size of the control group n=9, experimental group n=10; Data are presented as median (95% confidence intervals).

P¹= Analyze the differences within groups between baseline and final results. Wilcoxon signed-rank test was used.

*P<0.05, U de Mann-Whitney analyze the differences between groups.

P²= These data were log-transformed before statistical analyses was ANOVA for repeated measures to determine the time x group interaction.

242
 243
 244 The digital ulcers in the experimental group healed within 28 days, while those in the control
 245 group healed within 84 days. During the follow-up period, ulcer recurrence was observed in one

246 experimental group patient compared with in three control group patients. These results were
247 statistically significant (Table 4).

248

Table 4. Ischemic Digital Ulcers in Sclerosis Systemic

Group	Day 0	Day 28	Day 56	Day 84	Day 112	Day 140	Day 168
Experimental (n 10)	3	0	0	0	0	1	0
Control (n 9)	4	4	2	1	2	2	6
<i>p</i> value*	0.50	0.03	0.21	0.47	0.248	0.45	0.003

*statistical analysis was performed with the exact fisher test

249

250 Clinically, the treated hands of the experimental group patients exhibited larger volumes,
251 warmer temperatures, and faster capillary filling than the contralateral hands of the same
252 patients (Figure 2 and Video 1).

253

254 Both groups exhibited late capillaroscopic patterns. There was no significant change in the
255 number of nailfold capillary loops between the groups at the study's end. One experimental
256 group patient exhibited an improved capillaroscopic pattern changing from late to early, while
257 one control group patient exhibited a worsened capillaroscopic pattern changing from early to
258 late.

259

260 **DISCUSSION**

261

262 The application of decanted fat,[\[22\]](#) centrifuged fat,[\[14\]](#) and the ADSVF,[\[15, 25, 28\]](#) has
263 consistently and significantly improved pain, RP, and the healing of digital ulcers in the hands of

264 patients with SS, thereby improving their quality of life. Other inconsistently observed benefits,
265 such as decreased digital circumferences, improvements in digital mobility and strength,
266 improvements in the formation of new subungual capillaries, and improvements in function
267 based on Cochin scale scores, have also been reported.[\[14, 15, 23\]](#)

268
269 However, previous studies have been uncontrolled with a short follow-up period of 6
270 months.[\[14, 15\]](#) There has been only one controlled study that involved the use of decanted
271 grafts.[\[23\]](#) Within 8 weeks, digital ulcer healing was observed in 92% of the experimental group
272 patients compared to in 7.7% of the control group patients. Furthermore, at 20 weeks, pain
273 levels were decreased, and the number of unguual capillaries was increased in the experimental
274 group compared with in the control group.[\[23\]](#)

275
276 The present controlled study with a 6-month follow-up period included patients with diffuse
277 and limited SS as well as moderate vascular and articular involvement, including some with
278 severe internal organ involvement. The results observed in the experimental group were similar
279 to those reported in uncontrolled studies. There were statistically significant improvements in
280 pain, , digital ulcer healing and SF-36 scores in the experimental group. However, when the
281 variables were compared with those of the control group, only the improvement in pain was
282 statistically significant. Clinical important improvements were observed in quality of life, as well
283 as in intensity, duration and frequency of RP. In the experimental group. We believe that this
284 may be related to the sample size and suggest that it is necessary to conduct further studies

285 with larger numbers of patients. This study was carried out in mid-October with the final
286 evaluation conducted in May when the environmental temperature was warmer.

287
288 We are convinced that fat micrografts can be enriched with the ADSVF in order to acquire the
289 widely known volumetric effect of lipo-injections as well as the benefits of tissue regeneration
290 produced by the ADSVF. This mixture has already been suggested by Magalon.[25] In our study,
291 the volume infiltrated into each digit was 3 ml. This cellular mixture was administered adjacent
292 to each neurovascular digital pedicle, rather than only into the digital web spaces based on the
293 procedure performed by Bank.[22] Our patients presented with moderately intense vascular
294 and joint conditions and had Cochin scores ranging up to 63. In patients with Cochin scores
295 above 30, the fingers exhibit structured joint stiffness and significant sclerodactyly. Even in
296 these patients, it was possible to administer the cell suspension without causing adverse effects,
297 such as ischemia or compartment syndrome, and without the need for a relaxing incision, as
298 pointed out by Del Papa.[14, 23]

299 Unlike the conclusion of Malagon,[25] we consider that fat micrografts enriched with the ADSVF
300 are useful for the treatment of mild, moderate, and severe injuries in patients with ischemic
301 hands resulting from SS, including in those with structured joint stiffness. Although no
302 improvements were observed in movement in the present study, additional clinically relevant
303 benefits, such as decreased pain and improved RP, digital ulcer healing were observed.

304

305 The site and technique used for acquiring the lipoaspirate affect the quality of the ADSVF in
306 terms of its use for regenerative treatment.[29] Liposuction collection sites have been reported
307 in the knee, hip, femoral region, and abdomen.[14, 24, 25] In our study, fat grafts were mainly
308 obtained from the periumbilical region that is suggested to be the optimal site. Similar
309 techniques have been used for fat acquisition in all studies, including the present work.

310
311 Granel et al. processed the ADSVF with a Celution 800/CRS system.[24] Malagon et al. noted
312 that the process requires an evaluation in a cell biology laboratory.[25] In this study, we isolated
313 the ADSVF in a cell biology laboratory. The mean number of viable cells in the ADSVF that we
314 isolated was $228.05 \times 10^6 \pm 10.8$ compared with 50.5 ± 23.8 (16.7.92.6) in previous studies.[24]
315 Even when there was a larger number of cells in the ADSVF, in addition to those in the fat
316 micrografts, it did not affect our final results.

317
318 The techniques performed by the Granel and Magalon group for the characterization and
319 determination of the proportion of the ASCs contained in the ADSVF were consistent with the
320 requirements of the International Federation for Adipose Therapeutics and Science and the
321 International Society for Cellular Therapy and with the Bourin report.[24, 25, 30] In the present
322 study, cell characterization was performed using the following markers: CD34, CD44, CD45,
323 CD73, CD90, CD105, and human leukocyte antigen (HLA)-DR. Their values, together with their
324 adherence to plastic and differentiation toward adipocytes in the laboratory, indicate that the
325 cellular mixture in the ADSVF from our patients, which included mesenchymal stromal cells,

326 endothelial progenitor cells, pericytes, hematopoietic, and immune cells, is similar to those
327 reported previously.[[20](#), [24](#), [25](#), [30](#)] Therefore, the obtained results may be explained by the
328 local angiogenic, anti-inflammatory, antifibrotic, immunomodulatory, and regenerative
329 properties of the autologous injected ASCs. It has been demonstrated that the vascular or
330 regenerative properties of the ADSVF are not compromised by SS.[20] Although it is assumed
331 that the administration of the ADSVF may have some systemic effects, the involvement of
332 internal organs did not improve or worsen in association with SS in our patients.

333
334 The treated hands of the experimental group patients exhibited a clinically greater volume than
335 the contralateral hands in the same group and hands of the control group patients. This greater
336 volume could prevent the recurrence of ulcers on the bony prominences.

337
338 Our study has proven that when combined with conventional medical therapies, the
339 administration of fat micrografts enriched with the ADSVF into the hands of patients with SS can
340 significantly improve pain. Studies with larger numbers of patients are necessary in order to
341 confirm that this method can improve digital ulcer healing, RP, digital perfusion, the vascular
342 density of the nail bed, and the function of the hand.

343
344 Based on the aforementioned findings, the regenerative medicinal benefits of the ADSVF are an
345 essential aid for rheumatologists and plastic surgeons before or during the treatment of hand d
346 eformities in patients with SS.

347 **CONCLUSION**

348 The administration of fat micrografts enriched with the ADSVF is a reproducible, safe, and well-
349 tolerated treatment option for the hands of patients with SS. This procedure offers the
350 advantages of the volumetric effect of fat and its regenerative properties. Decreased pain levels
351 and increased healing of digital ulcers, were observed in our patients with SS as well as a
352 tendency toward improvements in RP, and quality of life. Although it is necessary to conduct
353 further studies with larger numbers of patients, we conclude that this treatment is safe and can
354 be administered as a preventive strategy to avoid the progression of hand deformities in
355 patients with SS.

356

357 **Abbreviations**

- 358 • SS: Systemic Sclerosis
- 359 • RP: Raynaud phenomenon
- 360 • ASCs: Adipose stem cells
- 361 • ADSVF: Adipose-Derived Stromal Vascular Fraction
- 362 • DUH: Digital Ulcer Healing
- 363 • PBS: Phosphate-buffered saline

364

365

366

367

368 **DECLARATIONS**

369 **Ethics approval and consent to participate**

370 This research was approved by Institutional Review Committee and The Research Ethical
371 Committee of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, with the
372 reference, SCI-1505-15/15-1.

373 Informed consent to participate in the study was approved by the same committees and was
374 obtained from all the participants.

375 **Consent for publication**

376 The patients involved in this research in both groups have signed our institutional consent form
377

378 **Availability of data and materials**

379 All data generated or analyzed during this study are included in this published article and its
380 supplementary information files as: [Additional File 1 Table A](#), [Additional File 2 Table B](#),
381 [Additional File 3 Statistics](#), and [Additional File 4 Patient and Public Involvement 1](#)

382 **Competing interests**

383 The authors declare that they have no competing interests

384

385 **Funding**

386 Consejo Nacional de Ciencia y Tecnologia (CONACYT) funding this research, with the Sectorial
387 Research Fund in Health and Social Security I0000/739/2017.

388

389 **Author's contributions:**

390 MI: Performed the protocol and the procedure, draft of the manuscript; critically revising the
391 manuscript, data interpretation and discussion of results.

392 ITV: Isolation of Adipose Derived Stromal Vascular Fraction, and revision of the manuscript.

393 PBG: Collaboration in the procedure and postoperative control.

394 TSRR: Performed the protocol and selection of candidate patients.

395 EATA: Isolation of Adipose Derived Stromal Vascular Fraction, and revision of the manuscript.

396 ARTP: Performed the protocol and analysis of the results.

397 AZD: Performed cellular characterization.

398 MGC: performed the statistical analysis

399 AMHC: Performed the protocol, enroll patients and obtain informed consent.

400

401 **Acknowledgements**

402 The authors thank to Claudia Chavez-Muñoz, MD, for her scientific support, and the Consejo
403 Nacional de Ciencia y Tecnologia (CONACYT) for their funding support.

404

405

406 REFERENCES

- 407
- 408 1. Amanzi L, Braschi F, Fiori G, Galluccio F, Miniati I, Guiducci S, *et al.* Digital ulcers in
- 409 scleroderma: staging, characteristics and sub-setting through observation of 1614 digital
- 410 lesions. *Rheumatology (Oxford)* 2010;49:1374–82.
- 411
- 412 2. Galluccio F, Matucci-Cerinic M. Two faces of the same coin: Raynaud phenomenon and
- 413 digital ulcers in systemic sclerosis. *Autoimmun Rev* 2011;10:241–3.
- 414
- 415 3. Botzoris V, Drosos A. Management of Raynaud’s phenomenon and digital ulcers in
- 416 systemic sclerosis. *Joint Bone Spine* 2011;78:341–6.
- 417
- 418 4. Nitsche A. Raynaud, digital ulcers and calcinosis in scleroderma. *Reumatol Clin*
- 419 2012;8:270–7.
- 420
- 421 5. Avouac J, Clements PJ, Khanna D, Furst DE, Allanore Y. Articular involvement in systemic
- 422 sclerosis. *Rheumatology* 2012;51:1347-56.
- 423
- 424 6. Morrisoe K, Nikpour M, Proudman S. Musculoskeletal Manifestation of Systemic
- 425 Sclerosis. *Rheum Dis Clin N Am* 2015;41:507-18.
- 426
- 427 7. Loránd V, Czirják L, Minier T. Muskuloskeletal involvement in systemic sclerosis. *Presse*
- 428 *Med* 2014;43: e315-e328.
- 429

- 430 8. Shima Y, Hosen N, Hirano T, Arimitsu J, Nishida S, Hagihara K, *et al.* Expansion of range
431 of joint motion following treatment of systemic sclerosis with tocilizumab. *Modern*
432 *Rheumatology* 2015;25:134-137.
- 433
434 9. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI Mizuni H, *et al.* Human adipose tissue
435 is a source of multipotent stem cells. *Mol Biol Cell* 2002;13:4279-4295.
- 436
437 10. Kokai L, Marra K, Rubin J. Adipose stem cells: biology and clinical applications for tissue
438 repair and regeneration. *Transl Res* 2014;163:399-408.
- 439
440 11. Suga H, Glotzbach, JP, Sorkin M, Longaker MT, Gurtner GC. Paracrine mechanism of
441 angiogenesis in adipose-derived stem cell transplantation. *Ann Plast Surg* 2014;72: 234-
442 241.
- 443
444 12. Yang J, Zhang H, Zhao L, Chen Y, Liu H, Zhang T. Human adipose tissue-derived stem cells
445 protect impaired cardiomyocytes from hypoxia/reoxygenation injury through hypoxia-
446 induced paracrine mechanism. *Cell Biochem Funct* 2012;30:505-514.
- 447
448 13. Griffin M, Ryan CM, Pathan O, Abraham D, Denton CP, Butler PEM. Characteristics of
449 human adipose derived stem cells in scleroderma in comparison to sex and age matched
450 normal controls: implications for regenerative medicine. *Stem Cell Res Ther* 2017;8:23-
451 34.
- 452

- 453 14. Del Papa N, Di Luca G, Sambataro D, Zaccara E, Maglione W, Gabrielli A, *et al.* Regional
454 implantation of autologous adipose tissue-derived cells induces a prompt healing of
455 long-lasting indolent digital ulcers in patients with systemic sclerosis. *Cell Transplant*
456 2015; 24: 2297-2305.
- 457
458 15. Guillaume-Jugnot P, Daumas A, Magalon J, Sautereau N, Veran J, Magalon G, *et al.* State
459 of the art. Autologous fat graft and adipose tissue-derived stromal vascular fraction
460 injection for hand therapy in systemic sclerosis patients. *Curr Res Transl Med*
461 2016;64:35-42.
- 462
463 16. Piłkuła M, Marek-Trzonkowska N, Wardowska A, Renkielska A, Trzonkowski P. Adipose
464 tissue-derived stem cells in clinical applications. *Expert Opin Biol Ther* 2013;13:1357–
465 1370.
- 466
467 17. Bura A, Planat-Benard V, Bourin P, Silvestre JS, Gross F, Grolleau JL, *et al.* Phase I trial:
468 the use of autologous cultured adipose-derived stroma/stem cells to treat patients with
469 non-revascularizable critical limb ischemia. *Cytotherapy* 2014;16:245-257.
- 470
471 18. Zuk P. Adipose-Derived Stem Cells in Tissue Regeneration: A Review. *ISRN Stem Cells*
472 2013;2013:1-35.
- 473
474 19. Bora P, Majumdar AS. Adipose tissue-derived stromal vascular fraction in regenerative
475 medicine: a brief review on biology and translation. *Stem Cell Res Ther* 2017;8:145.
- 476

- 477 20. Magalon J, Velier M, SImoncini S, François P, Bertrand B, Daumas A,*et al.* Molecular
478 profile and proangiogenic activity of the adipose-derived stromal vascular fraction used
479 as an autologous innovative medicinal product in patients with systemic sclerosis. *Ann*
480 *Rheum Dis* 2019;0:1–8.
- 481
- 482 21. Guillaume-Jugnot P, Daumas A, Magalon J, Jouve J, Nguyen PS, Truillet R, *et al.*
483 Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis:
484 12-month follow-up. *Rheumatology (Oxford)* 2016; 55: 301-306.
- 485
- 486 22. Bank J, Fuller SM, Henry GI, Zachary LS. Fat grafting to the hand in patients with Raynaud
487 phenomenon: a novel therapeutic modality. *Plast Reconstr Surg* 2014;133:1109-1118.
- 488
- 489 23. Del Papa N, Di Luca G, Andracco R, Zaccara E, Maglione W, Pignataro F, *et al.* Regional
490 grafting of autologous adipose tissue is effective in inducing prompt healing of indolent
491 digital ulcers in patients with systemic sclerosis: results of a monocentric randomized
492 controlled study. *Arthritis Res Ther* 2019;21:7-18.
- 493
- 494 24. Granel B, Daumas A, Jouve E, Harlé JR, Nguyen PS, Chabannon C, *et al.* Safety,
495 tolerability and potential efficacy of injection of autologous adipose-derived stromal
496 vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I
497 trial. *Ann Rheum Dis* 2015; 74:2175-2182.
- 498

- 499 25. Magalon G, Daumas A, Sautereau N, Magalon J, Sabatier F, Granel B. Regenerative
500 Approach to Scleroderma with Fat Grafting. *Clin Plast Surg* 2015;42:353-364.
- 501
502 26. Daumas A, Magalon J, Jouve E, Trulliet R, Casanova D, Giraud D, *et al.* Long-term
503 follow-up after autologous adipose-derived stromal vascular fraction injection into
504 fingers in systemic sclerosis patients. *Curr Res Transl Med* 2017;65:40-43.
- 505
506 27. Manetti M, Guiducci S, Ruffo M, Rosa I, Fausone-Pelligrini MS, Matucci-Cerinic M, *et al.*
507 Evidence for progressive reduction and loss of telocytes in the dermal cellular network of
508 systemic sclerosis. *J Cell Mol Med* 2013;17:482-496.
- 509
510 28. Song JI, Volz S, Liodaki ME, Mailänder P, Kalousis K. Stem cells therapy: the future in the
511 management of systemic sclerosis? A case report. *Hell J Nucl Med* 2017;20:164.
- 512
513 29. Alharbi Z, Opländer C, Almakadi S, Fritz A, Vogt M, Pallua N. Conventional vs. micro-fat
514 harvesting: how fat harvesting technique affects tissue-engineering approaches using
515 adipose tissue-derived stem/stromal cells. *J Plast Reconstr Aesthet Surg* 2013;66:1271-
516 1278.
- 517
518 30. Bourin P, Bunnell BA, Casteilla L, Dominici M, Katz A, March KL, *et al.* Stromal cells from
519 the adipose tissue-derived stromal vascular fraction and culture expanded adipose
520 tissue-derived stromal/stem cells: a joint statement of the International Federation for

521 Adipose Therapeutics and Science (IFATS) and the International Society for Cellular
522 Therapy (ISCT). *Cytotherapy* 2013;15:641-648.

523

524 FIGURE LEGEND

525 Figure 1. Flow chart of the methodology. (A) Fat grafts are obtained by abdominal liposuction.
526 (B) A 60 ml volume is sent to the laboratory. (C) The enzymatic digestion of fat is performed by a
527 collagenase separation method. (D) The initial adipose-derived stromal vascular fraction
528 (ADSVF) is divided into two samples. (E) The first is a 1 ml sample for the characterization and
529 control of the cell culture. (F) The second is a 2 ml sample that is reserved for administration to
530 the patient in a lipoaspirate mixture by infiltration into the hand. The differentiation process is
531 depicted in the last row. Differentiation. (G) Control culture without adipogenic stimulation
532 stained with oil red (OR) at day 20. (H) Culture with adipogenic stimulation stained with OR on
533 day 20. (I) Spectrophotometric analysis of the two groups depicted in a graphic. There was *a*
534 *higher OR absorption level in the differentiated group* ($p = 0.0001$).

535

536 Figure 2. Clinical results. (A, B) Patient 1, female with age range 56-60 y/o. The right hand was
537 injected with micrografts enriched with the adipose-derived stromal vascular fraction. It
538 exhibited a higher volume and was warmer than the left hand. (C) Patient 2, female with age
539 range 31-35 y/o. Clinical status before the treatment. The hand presented with dermo-
540 epidermal abrasions and digital ulcers. (D) The same patient with healing digital ulcers.

541

542 **Additional files**

543

544 Additional file 1. Table A. The total viable nucleated cell numbers and cellular characteristics of





545 the ADSVF

546 Additional file 2. Table B. Complete Results control and experimental groups

547 Additional file 3. Statics. Spreadsheet of data collection

548 Additional file 4. Patient and public involvement 1

549



A**B****C****D**